BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 14, 2012
View Archived Issues
New therapeutic target identified for schizophrenia
Read More
Nanoparticles targeting microRNA inhibit lymphoma
Read More
Novo Nordisk announces highlights of second quarter 2012
Read More
MultiCell Technologies updates on candidate dsRNA anticancer therapies
Read More
Protalix BioTherapeutics to begin clinical testing of candidate Fabry's disease drug
Read More
Bionor Pharma to conduct HIV vaccine combination study
Read More
AspenBio Pharma submits pre-IDE package for appendicitis test
Read More
Biofrontera and Pelpharma Handels sign distribution agreement
Read More
Scientists in China isolate new saponins from bunge fruit
Read More
Canadian university patents novel melanocortin MC4 receptor modulators
Read More
Compounds for ADHD treatment synthesized in France
Read More
New glutamate receptor antagonists presented by Taisho Pharmaceutical
Read More
Novel calcium channel antagonists developed at U.S. university
Read More
Nagasaki University reports new candidate anticancer products
Read More
Meritage Pharma launches trial in eosinophilic esophagitis
Read More
Recruitment complete in first stage of TACTT1 study
Read More
FDA extends PDUFA action date for Gattex NDA
Read More
Novel HCV entry inhibitor selected for further evaluation
Read More
New E.U. approval for Votrient
Read More
Second-generation Shigella vaccines designed in U.S.
Read More
PDUFA date for Santarus NDA extended
Read More
Tarceva approved in Canada for specific NSCLC subtype
Read More
FDA accepts for filing Teva's NDA for new oral contraceptive
Read More